SHC vs. PGNY, RDNT, AGL, QGEN, DVA, FMS, SGRY, IDYA, SMMT, and FOLD
Should you be buying Sotera Health stock or one of its competitors? The main competitors of Sotera Health include Progyny (PGNY), RadNet (RDNT), agilon health (AGL), Qiagen (QGEN), DaVita (DVA), Fresenius Medical Care (FMS), Surgery Partners (SGRY), IDEAYA Biosciences (IDYA), Summit Therapeutics (SMMT), and Amicus Therapeutics (FOLD). These companies are all part of the "medical" sector.
Progyny (NASDAQ:PGNY) and Sotera Health (NASDAQ:SHC) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, community ranking, institutional ownership and risk.
Progyny received 40 more outperform votes than Sotera Health when rated by MarketBeat users. Likewise, 74.56% of users gave Progyny an outperform vote while only 56.96% of users gave Sotera Health an outperform vote.
In the previous week, Progyny had 43 more articles in the media than Sotera Health. MarketBeat recorded 45 mentions for Progyny and 2 mentions for Sotera Health. Progyny's average media sentiment score of 0.94 beat Sotera Health's score of 0.10 indicating that Sotera Health is being referred to more favorably in the news media.
Progyny has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, Sotera Health has a beta of 2.08, indicating that its stock price is 108% more volatile than the S&P 500.
Progyny has higher revenue and earnings than Sotera Health. Progyny is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.
Progyny presently has a consensus target price of $44.11, indicating a potential upside of 60.52%. Sotera Health has a consensus target price of $17.70, indicating a potential upside of 55.26%. Given Sotera Health's stronger consensus rating and higher possible upside, analysts clearly believe Progyny is more favorable than Sotera Health.
Progyny has a net margin of 5.53% compared to Progyny's net margin of 5.09%. Progyny's return on equity of 48.47% beat Sotera Health's return on equity.
94.9% of Progyny shares are held by institutional investors. Comparatively, 91.0% of Sotera Health shares are held by institutional investors. 12.3% of Progyny shares are held by insiders. Comparatively, 55.1% of Sotera Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Progyny beats Sotera Health on 12 of the 18 factors compared between the two stocks.
Get Sotera Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for SHC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sotera Health Competitors List
Related Companies and Tools
